Pharmacokinetics and metabolism of [14C]ribavirin in rats and cynomolgus monkeys

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1395-1398

  Lin, Chin Chung ^a   Yeh, Li Tain ^a   Luu, Trong ^a   Lourenco, David ^a   Lau, Johnson Y N ^a  

^a Ribapharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MONKEY; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; CARBON RADIOISOTOPES; ERYTHROCYTES; MACACA FASCICULARIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RIBAVIRIN; SPECIES SPECIFICITY;

EID: 0037378921     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1395-1398.2003     Document Type: Article

References (13)

1. Catlin, D. H., R. Smith, and A. I. Samuels. 1980. 14C-ribavirin: distribution and pharmacokinetic studies in rats, baboon and man, p. 83-98. In R. A. Smith and W. Kirkpatrick (ed.), Ribavirin: a broad spectrum antiviral agent. Academic Press, New York, N.Y.
2. Ferrara, E. A., J. S. Oishi, R. W. Wannemacher, Jr., and E. L. Stephen. 1981. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob. Agents Chemother. 19:1042-1049.
3. Laskin, O. L., J. A. Longstreth, C. C. Hart, D. Scavuzzo, C. M. Kalman, J. D. Connor, and R. B. Roberts. 1987. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 41:546-555.
4. Miller, J. P., L. J. Kigwana, D. G. Streeter, R. K. Robins, L. N. Simon, and J. Roboz. 1977. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann. N. Y. Acad. Sci. 284:211-229.
5. Page, T., and J. D. Conner. 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Intl. J. Biochem. 22:379-383.
6. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-β-Dribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
7. Smith, R. A. 1980. Mechanism of action of ribavirin, p. 99-118. In R. A. Smith and W. Kirkpatrick (ed.), Ribavirin: a broad spectrum antiviral agent. Academic Press, New York, N.Y.
8. Stephen, E. L., D. E. Jones, C. J. Peters, G. A. Eddy, P. S. Loizeaux, and P. B. Jahrling. 1980. Ribavirin treatment of Toga-, Arena-, and Bunyavirus infections in subhuman primates and other laboratory animal species. In R. A. Smith and W. Kirkpatrick (ed.), Ribavirin: a broad spectrum antiviral agent. Academic Press, New York, N.Y.
9. Streeter, D. G., J. T. Witkowski, G. P. Khare, R. W. Sidwell, R. J. Bauer, R. K. Robins, and L. N. Simon. 1973. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA 70:1174-1178.
10. Tam, R. C., B. P. Pai, J. Bard, C. Lim, D. R. Averett, U. T. Phan, and T. Milovanovic. 1999. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 30:376-382.
11. Tam, R. C., C. Lim, J. Bard, and B. Pai. 1999. Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by Type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. J. Immunol. 163:3709-3717.
12. Tam, R. C., K. Ramasamy, J. Bard, B. Pai, C. Lim, and D. R. Averett. 2000. The ribavirin analogue ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob. Agents Chemother. 44:1276-1283.
13. Tam, R. C., J. Y. N. Lau, and Z. Hong. Mechanism of action of ribavirin in antiviral therapies. Antiviral Chem. Chemother., in press.